tebnow← All categories
Category

Disease & Epidemiology

65 articles indexed

Proposed $5 Billion Cut to NIH in 2027 Budget Faces Bipartisan Opposition

The White House has proposed a significant reduction of $5 billion to the National Institutes of Health (NIH) in its fiscal year 2027 budget request, which totals $41 billion. This budget plan includes a controversial proposal to reduce the number of NIH institutes and centers from 27 to 22, a move that is expected to face strong resistance from lawmakers across both parties. Key institutes targeted for elimination include the National Center for Complementary and Integrative Health, the Fogarty International Center, and the National Institute on Minority Health and Health Disparities. Additionally, the budget seeks to consolidate two institutes focused on drug and alcohol abuse into a new entity named the National Institute of Substance Use and Addiction Research. It also proposes relocating the National Institute of Environmental Health Sciences to the Centers for Disease Control and Prevention (CDC). The budget cuts extend to the Advanced Research Projects Agency for Health (ARPA-H), which is set to see its funding slashed from $1.5 billion to $945 million, potentially impacting innovative health research initiatives. These proposed changes are significant as they could hinder ongoing research efforts and limit the NIH's ability to address pressing health challenges. The NIH plays a crucial role in advancing medical research and public health, and such budget cuts could have far-reaching implications for healthcare professionals, researchers, and patients alike. As Congress prepares to review the budget, the likelihood of these proposals being enacted remains uncertain, with bipartisan pushback anticipated.

STAT News/2h ago

NIH / budget cuts / health research / Congress / fiscal policy

White House Proposes 12% Budget Cut for Health Agencies in 2027

The White House has proposed a significant budget cut of over 12% for the Department of Health and Human Services (HHS) in its 2027 federal budget request. This proposal mirrors previous budgetary suggestions made during the Trump administration and includes substantial reductions to the National Institutes of Health (NIH) and the elimination of a health research agency. Additionally, the budget outlines the establishment of a new agency focused on chronic diseases, named the Administration for a Healthy America. This budget proposal is crucial as it sets the tone for the administration's health priorities for the upcoming year, although it is Congress that will ultimately decide on the final appropriations. The proposed cuts could have far-reaching implications for health research funding and public health initiatives, potentially affecting a wide range of stakeholders, including researchers, healthcare providers, and patients. The NIH, a key player in medical research, may face challenges in funding ongoing and future studies, which could hinder advancements in various health fields. The creation of the new agency aims to address chronic diseases, which are a growing concern in the U.S., but the effectiveness of this initiative will depend on the overall budget allocation. As Congress reviews the proposal, healthcare professionals and organizations will be closely monitoring the developments to understand the potential impacts on health services and research funding.

STAT News · 4h ago

White House Proposes 12% Budget Cut for Health Agencies in 2027

In a recent budget proposal for 2027, the White House has requested a significant reduction of over 12% in funding for the Department of Health and Human Services (HHS). This proposed budget mirrors the previous year's suggestions from the Trump administration, indicating a continued trend towards austerity in federal health spending. Key components of the proposal include substantial cuts to the National Institutes of Health (NIH) and the elimination of a health research agency, which could have far-reaching implications for medical research and public health initiatives. Additionally, the proposal introduces the establishment of a new agency focused on chronic diseases, named the Administration for a Healthy America. This agency aims to address the growing burden of chronic conditions, which affect millions of Americans and contribute significantly to healthcare costs. The budget serves as an agenda-setting document, outlining the administration's priorities for the upcoming year, although it is Congress that will ultimately determine the final appropriations. The proposed cuts raise concerns among healthcare professionals and researchers about the potential impact on public health programs and scientific research funding. As Congress deliberates on the budget, stakeholders in the healthcare sector will be closely monitoring the discussions to understand how these changes may affect their work and the health outcomes of the population. The outcome of this budget proposal could set the tone for health policy and funding for years to come.

STAT News · 4h ago

Industry Movements: Proxygen Appoints Chiara Conti as Chief Scientific Officer

In a notable shift within the pharmaceutical sector, Proxygen has announced the appointment of Chiara Conti as its new Chief Scientific Officer. Conti brings a wealth of experience from her previous role as Senior Director at Blueprint Medicines, where she contributed significantly to the company's research and development efforts. This strategic hire reflects Proxygen's commitment to advancing its scientific initiatives and enhancing its leadership team. The pharmaceutical industry is continuously evolving, and such appointments are crucial for fostering innovation and driving growth. As companies seek to fill key positions, the movement of talent can have a substantial impact on their operational capabilities and future success. Stakeholders and industry professionals are keenly observing these changes, as they often signal shifts in research focus and corporate strategy.

STAT News · 6h ago

Trump Administration Implements 100% Tariffs on Imported Brand-Name Drugs with Key Exceptions

The Trump administration has announced a controversial 100% tariff on imported brand-name drugs, a move aimed at reducing pharmaceutical costs and encouraging domestic manufacturing. However, many large drug manufacturers are exempt from these tariffs due to prior agreements to establish production facilities in the U.S. and commit to lowering drug prices. For those companies that have not yet made such commitments, there is an opportunity to reduce the tariff to 20% by pledging to bring production to the U.S. during Trump's term. This tariff initiative is part of a broader strategy by the Trump administration to rein in pharmaceutical prices ahead of the midterm elections. In addition to the tariffs, the administration is also negotiating drug-pricing agreements with smaller pharmaceutical companies, which were not included in the initial round of deals. These negotiations aim to provide smaller firms with a chance to secure lower prices and avoid tariffs or new pricing policies under Medicare. The outcome of these negotiations remains uncertain, as the number of companies involved and the timeline for potential agreements are still unclear. The administration's approach reflects a desire to replicate the successful strategy used with larger drugmakers, focusing on voluntary agreements to achieve lower prices and increased domestic production. This development is significant for healthcare professionals and stakeholders in the pharmaceutical industry, as it could reshape the landscape of drug pricing and manufacturing in the U.S.

STAT News · 6h ago

Trump Administration Implements 100% Tariffs on Imported Brand-Name Drugs with Key Exceptions

The Trump administration has announced a controversial 100% tariff on imported brand-name drugs, a move aimed at reducing pharmaceutical costs and encouraging domestic manufacturing. However, the implementation of these tariffs comes with significant caveats. Major drug manufacturers that have established agreements with the U.S. to build manufacturing facilities domestically will be exempt from these tariffs. Additionally, companies that have not yet made such arrangements can reduce their tariffs to 20% if they commit to relocating production to the U.S. during Trump's term. This policy shift is part of a broader strategy by the Trump administration to rein in pharmaceutical prices ahead of the midterm elections. The administration is also engaging in negotiations with smaller pharmaceutical companies, offering them a chance to pledge lower prices in exchange for avoiding tariffs or new pricing policies under Medicare. This approach mirrors the earlier agreements made with larger drugmakers, focusing on voluntary, confidential arrangements to achieve lower prices and increased domestic production. The implications of these tariffs and negotiations are significant for the pharmaceutical industry, as they could reshape pricing strategies and manufacturing locations. While the administration's efforts may lead to lower drug prices for consumers, the actual number of companies involved in negotiations and the timeline for reaching agreements remain uncertain. As the situation develops, healthcare professionals and stakeholders in the pharmaceutical sector will need to monitor these changes closely to understand their potential impact on drug availability and pricing.

STAT News · 6h ago

World Autism Awareness Day Highlighted by HHS with Fitness Event Amid Controversy

On World Autism Awareness Day, the U.S. Department of Health and Human Services (HHS) hosted a unique event that combined a fitness activity with a celebration of autism awareness. Health Secretary Robert F. Kennedy Jr. and other officials participated in the event, which encouraged attendees to wear athletic attire. The rationale behind incorporating physical activity was to emphasize research indicating that exercise can enhance overall well-being for individuals with autism. However, the event drew mixed reactions, with some questioning the appropriateness of the focus on fitness given Kennedy's controversial history regarding autism and vaccines. Critics pointed out that while exercise can be beneficial for everyone, Kennedy has previously promoted discredited theories linking vaccines to autism and has been involved in controversial discussions about autism therapies. This has led to skepticism about his commitment to the autism community. The event's unusual combination of fitness and autism awareness left many feeling perplexed, with some autistic individuals describing it as 'deeply weird.' The event reflects ongoing efforts by HHS to engage with the autism community, but it also highlights the complexities and sensitivities surrounding autism advocacy, particularly in light of past misinformation. As the conversation around autism continues to evolve, the implications of such events on public perception and policy remain significant. Moving forward, it will be crucial for health officials to align their messaging and activities with the needs and perspectives of the autism community to foster genuine support and understanding.

STAT News · 7h ago

Subscription Pricing for Lenacapavir Could Enhance Access to HIV Prevention Amid Funding Cuts

Recent studies have shown that lenacapavir, a long-acting injectable antiretroviral, has the potential to significantly reduce HIV infections, particularly among cisgender adolescent girls and young women, with a reported zero infections in the PURPOSE-1 trial. However, the announcement of its annual price at $28,218 has raised concerns about accessibility, especially following drastic funding cuts for HIV care and research in 2025. The situation mirrors past challenges faced by other breakthrough treatments, such as cabotegravir and hepatitis C antivirals, which struggled with high costs and limited access due to insurance barriers. To address these issues, experts are advocating for a subscription pricing model, akin to the 'Netflix model' used in some regions for hepatitis C treatments. This model allows government insurers to pay a fixed fee for unlimited access to medications, thereby reducing per-patient costs and expanding access without overwhelming healthcare systems. Evidence from Louisiana and Australia indicates that such strategies have successfully increased treatment uptake and improved health outcomes. Lenacapavir's manufacturing costs are estimated to be as low as $25 per year, making it particularly suitable for subscription pricing. This approach could facilitate negotiations between insurers and manufacturers, potentially leading to broader access in both high-income and upper-middle-income countries. As the healthcare community seeks to end the HIV epidemic, implementing subscription pricing for lenacapavir could be a pivotal step towards achieving this goal.

STAT News · 11h ago

Supreme Court Ruling on Conversion Therapy Impacts Medical Speech Regulations

The U.S. Supreme Court's recent decision against Colorado's ban on licensed mental health providers practicing gender and sexuality conversion therapy has significant implications for the regulation of healthcare providers' speech. In an 8-1 ruling, the Court determined that the ban infringed upon the therapist's right to free speech, categorizing therapy as a form of speech rather than conduct. This distinction may limit the authority of state medical boards to regulate various aspects of healthcare, particularly those involving talk therapy, telehealth, and even physician advice on contentious topics like COVID-19 and reproductive health. Legal experts suggest that this ruling could create a precedent that allows healthcare professionals to challenge state regulations that restrict their speech, potentially affecting a wide range of clinical practices. The ruling emphasizes that viewpoint discrimination, particularly against LGBTQ+ identities, is generally impermissible under the First Amendment. As a result, the decision may embolden clinicians to assert their rights in situations where they feel their speech is being curtailed, especially in states with restrictive laws regarding counseling on sensitive issues. The implications of this ruling extend beyond conversion therapy, as it raises questions about the boundaries of clinician speech in various contexts, including telehealth services. Ongoing legal challenges in California and New Jersey regarding telehealth regulations may gain traction in light of the Chiles decision, as plaintiffs argue that their First Amendment rights are being violated. Critics, including Justice Ketanji Brown Jackson, warn that this ruling could undermine state efforts to regulate medical care effectively, posing risks to public health and safety. As the legal landscape evolves, healthcare professionals and organizations will need to navigate the complexities introduced by this ruling, which could redefine the standards of care and the extent of state regulatory power over medical speech. The full impact of the Chiles decision will likely unfold in future legal battles, as clinicians seek to assert their rights in an increasingly contentious healthcare environment.

STAT News · 11h ago

EPA Proposes Inclusion of Microplastics in Drinking Water Contaminant List

The Environmental Protection Agency (EPA) has proposed adding microplastics and pharmaceuticals to its Contaminant Candidate List (CCL) for drinking water, marking a significant step towards potential regulation of these substances. This proposal responds to growing public concern regarding the safety of drinking water, as highlighted by EPA Administrator Lee Zeldin. The draft list, which opens a 60-day public comment period, is expected to be finalized by mid-November. The CCL identifies contaminants that are not currently regulated under the Safe Drinking Water Act, and the inclusion of microplastics could pave the way for future regulatory measures. Research has indicated the presence of microplastics in drinking water and their potential health implications, with studies linking them to various health issues. Additionally, pharmaceuticals often enter the water supply through human excretion, and conventional wastewater treatment methods are inadequate in removing these contaminants. While the EPA has historically been slow to regulate pollutants from the CCL, advocates view this proposal as a crucial first step towards addressing plastic pollution in public water supplies. Despite the positive reception from some environmental advocates, skepticism remains regarding the EPA's commitment to meaningful action. Critics, including Erik Olson from the Natural Resources Defense Council, caution that the process may lead to inaction, as has been the case in previous cycles. The EPA's announcement coincides with the MAHA movement led by Health Secretary Robert F. Kennedy Jr., which has been advocating for stricter environmental regulations. Kennedy's recent initiatives, including a $144 million effort to study and mitigate microplastics in the human body, underscore the urgency of addressing this issue. The new draft list also includes other contaminants such as PFAS and disinfection byproducts, reflecting a broader concern about water quality. As the EPA prepares to finalize the list, the agency faces pressure to take decisive action to protect public health and the environment from the growing threat of plastic pollution.

STAT News · 23h ago

EPA Proposes Inclusion of Microplastics in Drinking Water Contaminant List

The Environmental Protection Agency (EPA) has proposed adding microplastics and pharmaceuticals to its Contaminant Candidate List (CCL) for drinking water, marking a significant step towards potential regulation of these substances. This decision, announced by EPA Administrator Lee Zeldin, responds to growing public concern over the safety of drinking water and aligns with the goals of Health Secretary Robert F. Kennedy Jr.'s MAHA movement, which advocates for stricter environmental protections. The draft of the sixth version of the CCL will be open for public comment for 60 days, with a final list expected by mid-November. Microplastics have been detected in various environments, including drinking water, and studies suggest potential health risks associated with their presence in human tissues. Similarly, pharmaceuticals often enter water supplies through human excretion and are not effectively removed by conventional wastewater treatment processes. While the EPA's CCL serves to prioritize research and regulatory decisions, the agency has historically been slow to impose limits on contaminants, raising skepticism among environmental advocates about the effectiveness of this initiative. Experts like Judith Enck, former EPA regional administrator, view the inclusion of microplastics as a positive first step towards regulation, while Dr. Philip Landrigan emphasizes the need for broader action against plastic production to mitigate pollution. The EPA's announcement coincides with ongoing discussions about a global treaty on plastic pollution, although the U.S. has resisted limits on production. The new draft list includes microplastics, pharmaceuticals, PFAS, disinfection byproducts, and numerous chemicals and microbes, reflecting a comprehensive approach to addressing contaminants in drinking water. As the EPA prepares to finalize the CCL, stakeholders from various sectors, including the American Chemistry Council, express support for standardized monitoring of microplastics. However, the effectiveness of these measures remains uncertain, particularly in light of previous regulatory inaction. The upcoming MAHA agenda from the EPA is expected to tackle a range of environmental issues, including plastic pollution, as the agency navigates the complexities of public health and environmental safety.

STAT News · 23h ago

Smaller Drugmakers Engage in Pricing Negotiations with Trump Administration to Avoid Tariffs

The Trump administration is currently in negotiations with smaller pharmaceutical companies to establish new drug-pricing agreements. This initiative, revealed by sources familiar with the discussions, aims to provide these companies an opportunity to pledge lower prices in exchange for avoiding tariffs and new pricing policies under Medicare. This move follows a similar strategy previously employed with larger drug manufacturers, focusing on voluntary and confidential agreements to drive down prices and encourage domestic production. The significance of these negotiations lies in the potential for smaller drugmakers, who have been grappling with uncertainty regarding federal policies, to gain clarity and stability in their pricing strategies. By participating in these discussions, these companies can secure more favorable conditions that may help them navigate the complex regulatory landscape while also contributing to the administration's goals of reducing drug costs for consumers. As the negotiations progress, the outcome could have far-reaching implications for the pharmaceutical industry, particularly for smaller players who often lack the resources to absorb the impacts of tariffs and pricing reforms. The administration's approach reflects a broader trend towards engaging with various stakeholders in the healthcare sector to achieve lower drug prices and enhance domestic manufacturing capabilities. The next steps will involve finalizing agreements and determining how these new pricing structures will be implemented across the industry.

STAT News · 1d ago

Trump Administration Implements 100% Tariffs on Imported Brand-Name Drugs with Exceptions

In a significant move, the Trump administration has announced a 100% tariff on imported brand-name drugs, effective immediately. However, this policy comes with notable exceptions that may limit its impact on the pharmaceutical industry. Major drug manufacturers that have established agreements with the U.S. government to build domestic manufacturing facilities will be exempt from these tariffs. Additionally, companies that have not yet made such commitments can reduce their tariffs to 20% if they pledge to relocate production to the U.S. during Trump's term. This initiative is part of a broader strategy by the Trump administration to control pharmaceutical prices and encourage domestic production, particularly as the midterm elections approach. The administration aims to highlight its efforts to make medications more affordable for American consumers, a key concern for many voters. The tariffs are expected to affect various stakeholders in the healthcare sector, including pharmaceutical companies, healthcare providers, and patients who rely on imported medications. While the tariffs may incentivize some drug manufacturers to shift production to the U.S., the long-term effects on drug prices and availability remain uncertain. The healthcare industry will be closely monitoring how these tariffs influence market dynamics and whether they lead to tangible reductions in medication costs for consumers. As the situation develops, further analysis will be necessary to assess the implications for both the pharmaceutical industry and public health.

STAT News · 1d ago

FDA Reassesses Criteria for 'Breakthrough' Medical Devices

The FDA is evolving its criteria for what qualifies as a 'breakthrough' device, a designation that can expedite the approval process for innovative medical technologies. This shift is significant as it aims to enhance patient access to cutting-edge treatments and improve healthcare outcomes. The 'breakthrough' designation is particularly important for devices that offer significant advantages over existing options, potentially transforming patient care in various medical fields. The implications of this change are far-reaching, affecting manufacturers, healthcare providers, and patients alike. By streamlining the approval process, the FDA hopes to encourage innovation and investment in medical technology, which has been crucial in addressing unmet medical needs. As the healthcare landscape continues to evolve, the role of technology in improving patient outcomes becomes increasingly vital. Key stakeholders, including device manufacturers and healthcare professionals, will need to stay informed about these changes to leverage the new opportunities presented by the FDA's revised approach. The ongoing dialogue between the FDA and the medical device industry will be essential in shaping the future of medical technology and ensuring that advancements are both safe and effective for patient use.

STAT News · 1d ago

Eli Lilly's Orforglipron Approved for Weight Loss Amid Regulatory Scrutiny

The FDA has granted approval for Eli Lilly's new oral weight loss medication, orforglipron, marking a significant advancement in obesity treatment options. This approval comes at a time when the FDA is under scrutiny regarding its transparency and the management of conflicts within its advisory committees. The agency's approach to labeling breakthrough devices is also evolving, with a shift towards more ambitious AI-driven tools that may not yet have robust validation. This development is crucial as obesity continues to be a major public health issue, affecting millions and contributing to various comorbidities. In addition to the approval of orforglipron, the pharmaceutical landscape is also facing potential changes due to proposed import tariffs on patented medications by the Trump administration. A draft order suggests a 100% tariff on certain drug imports, which could significantly impact drug pricing and availability in the U.S. The tariffs may be announced imminently, adding another layer of complexity to the healthcare market. As orforglipron enters the market, healthcare professionals and patients alike will be watching closely to see how it performs compared to existing treatments. The implications of the proposed tariffs could further complicate access to medications, particularly for those relying on imported drugs. The intersection of regulatory changes, new drug approvals, and potential tariffs will shape the future of obesity treatment and pharmaceutical economics in the coming months.

STAT News · 1d ago

Eli Lilly's Orforglipron Approved by FDA, Sparking Competition in Obesity Treatment Market

The FDA has granted approval for Eli Lilly's new oral weight loss medication, orforglipron, marking a significant advancement in obesity treatment options. This approval positions Lilly in direct competition with existing GLP-1 receptor agonists, which have gained popularity for their effectiveness in weight management. The approval is particularly relevant as obesity rates continue to rise globally, impacting millions and straining healthcare systems. The introduction of orforglipron could provide new hope for patients struggling with obesity, offering an alternative to injectable therapies. In addition to the approval news, the FDA is facing scrutiny regarding its transparency and the potential conflicts of interest within its advisory committees. This scrutiny comes at a time when the agency is also exploring the use of artificial intelligence in medical devices, raising questions about the validation of these technologies. As the landscape of obesity treatment evolves, the implications of these developments could reshape patient care and treatment protocols. Moreover, the pharmaceutical industry is bracing for potential changes in drug import tariffs, as the Trump administration is reportedly preparing to impose a 100% tariff on certain patented medications and their active ingredients. This move could significantly impact drug pricing and availability in the U.S., further complicating the market dynamics for new obesity treatments like orforglipron. Stakeholders in the healthcare sector will need to monitor these developments closely as they unfold.

STAT News · 1d ago

Trump Administration Proposes 100% Tariff on Patented Medicines; FDA Approves Lilly's Obesity Pill

The Trump administration is set to announce a significant policy shift with a proposed 100% tariff on imports of patented medicines and their active ingredients. This move, which could be revealed as early as Thursday, aims to incentivize domestic production by offering reduced tariffs for companies that relocate manufacturing to the U.S. or engage in 'most-favored nation' pricing agreements. While the tariffs will not affect generic drugs or certain specialty medications, the implications for pharmaceutical companies and healthcare costs could be profound, particularly as the industry navigates these new financial pressures. In a related development, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's new obesity treatment, orforglipron, branded as Foundayo. This approval comes amid increasing competition in the obesity treatment market, particularly against Novo Nordisk's Wegovy. Orforglipron's approval under the FDA's new voucher program highlights its alignment with national health priorities, and investors are optimistic about its potential to drive growth for Lilly. Unlike Wegovy, which has specific dietary restrictions, orforglipron offers a more flexible administration, potentially appealing to a broader patient population. As the healthcare landscape evolves with these developments, stakeholders will need to monitor the impact of the proposed tariffs on drug pricing and availability, as well as the competitive dynamics in the obesity treatment market. The next steps for both the tariff proposal and the market response to Lilly's new drug will be critical in shaping future healthcare policies and patient access to medications.

STAT News · 1d ago

Global Debate Sparks Over Proposed 'Preclinical Obesity' Diagnosis Framework

A recent proposal to redefine obesity has ignited a global debate among healthcare experts, focusing on the limitations of the traditional body mass index (BMI) measurement. Critics argue that BMI fails to accurately distinguish between individuals with high muscle mass and those with excess fat, leading to potential misdiagnoses. In response, a global commission from Lancet Diabetes and Endocrinology has suggested a new framework that emphasizes alternative metrics such as waist circumference and waist-to-hip ratios. The commission's proposal introduces the concept of 'preclinical obesity,' which identifies individuals who may have excess body fat and be at risk for serious health conditions, including cardiovascular disease, type 2 diabetes, and certain cancers, but who have not yet been diagnosed with these illnesses. This distinction aims to facilitate earlier interventions and more tailored treatment strategies for at-risk populations. The implications of this proposed classification are significant, as it could lead to a shift in how obesity is diagnosed and treated globally. Healthcare professionals may need to adapt their approaches to screening and managing obesity-related health risks. As the debate continues, further research and consensus will be crucial in determining the most effective methods for identifying and addressing obesity in diverse populations.

STAT News · 1d ago

Biotech Sector Sees Surge as Eli Lilly and Biogen Announce Major Acquisitions

In a significant turn of events for the biotech industry, the XBI index, which tracks biotech stocks, experienced a notable 7% increase on the last day of the first quarter. This surge was primarily driven by Eli Lilly's acquisition of Centessa Pharma and Biogen's takeover of Apellis Pharma. These mergers and acquisitions (M&A) have reignited investor interest in the biotech sector, which had been facing a potential quarterly loss prior to these announcements. The rise in M&A activity is particularly noteworthy as it contrasts with a decline in FDA drug approvals, highlighting a shift in focus within the industry. The implications of these acquisitions extend beyond immediate stock performance; they reflect a broader trend in the biotech landscape where companies are seeking strategic partnerships to bolster their pipelines amid regulatory challenges. Investors are closely monitoring these developments, especially as concerns about geopolitical factors, such as tensions with China and fluctuating gas prices, loom over the market. As the second quarter begins, stakeholders in the biotech sector are left to ponder the sustainability of this momentum. The year-over-year increase in M&A activity suggests a robust interest in consolidating resources and expertise, but the decline in new drug approvals raises questions about the long-term growth potential of the industry. The upcoming ACACIA heart study from Cytokinetics is also anticipated, as it may provide further insights into the evolving landscape of drug development and investment in biotech. Overall, the recent acquisitions signal a pivotal moment for biotech firms, as they navigate a complex environment marked by both opportunities and challenges. Investors and healthcare professionals alike will be watching closely to see how these strategic moves will shape the future of the industry.

STAT News · 1d ago

Celebrating Giovanni Battista Grassi's Legacy in Malaria Research

A mural portrait of Giovanni Battista Grassi, a pivotal figure in malaria research, has been unveiled at the National Institute for Infectious Diseases 'Lazzaro Spallanzani' in Rome, Italy. This artwork, part of a public project commemorating the institute's 80th anniversary, highlights Grassi's significant contributions to understanding malaria and its transmission through Anopheles mosquitoes. Grassi's work in the late 19th century was groundbreaking; he identified Plasmodium vivax as the causative agent of malaria and established the Anopheles mosquito as its vector, a discovery that faced skepticism from contemporaries, including Robert Koch. Grassi's research was characterized by a multidisciplinary approach, investigating various parasites and their ecological roles. His formulation of Grassi's Law, which linked malaria transmission to infected humans and Anopheles mosquitoes, laid the groundwork for future malaria prevention strategies. He advocated for the use of physical barriers and chemical protection, conducting experiments that demonstrated the effectiveness of these methods in reducing malaria transmission in endemic areas. The mural not only honors Grassi's legacy but also serves as a reminder of the ongoing challenges in infectious disease research. As the world continues to grapple with malaria and other vector-borne diseases, revisiting Grassi's insights can inspire modern approaches to disease prevention and control. The installation of the mural is a fitting tribute to a scientist whose work remains relevant in the fight against malaria today.

Emerging Inf. Dis. · 4d ago

WHO Member States Extend Negotiations on Pathogen Access and Benefit Sharing Annex

Member States of the World Health Organization (WHO) have agreed to extend negotiations on the Pathogen Access and Benefit Sharing (PABS) annex of the WHO Pandemic Agreement, with discussions set to resume from April 27 to May 1, 2026. This decision comes ahead of the World Health Assembly (WHA) scheduled for May, where the annex is expected to be considered. The PABS annex is crucial for ensuring equitable sharing of pathogens with pandemic potential and the benefits derived from their use, such as vaccines and therapeutics. The WHO Pandemic Agreement, adopted last year, aims to address the shortcomings revealed by the COVID-19 pandemic and enhance global cooperation in pandemic preparedness and response. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized the importance of trust among Member States in achieving a successful PABS system. The ongoing negotiations reflect a commitment to creating a fair framework for pathogen sharing that prioritizes public health interests. During the recent negotiations, Member States discussed key issues including the definition and distribution of benefits from pathogen sharing, the contractual arrangements necessary for the PABS system, and governance structures to ensure transparency and effectiveness. With less than two months until the WHA, negotiators are working diligently to reach consensus on outstanding issues, reaffirming their dedication to solidarity and multilateralism in the face of future pandemics. The outcome of these negotiations will play a significant role in shaping global health policies and ensuring that the lessons learned from the COVID-19 pandemic lead to a more equitable and prepared world for future health crises.

WHO Outbreak News · 6d ago

WHO Reports Significant Progress in Health Policies for Refugees and Migrants

The World Health Organization (WHO) has released a report indicating a significant shift in how countries address the health needs of refugees and migrants. According to the data, over 60 countries, representing two-thirds of those surveyed, now incorporate refugees and migrants into their national health policies and laws. This report establishes a global baseline for tracking the progress of inclusive health systems, highlighting the importance of addressing the health needs of over 1 billion individuals who live as refugees or migrants worldwide. The report emphasizes that refugees and migrants face numerous barriers to accessing healthcare, including heightened risks of infectious and chronic diseases, mental health challenges, and unsafe living conditions. Dr. Tedros Adhanom Ghebreyesus, WHO's Director-General, stated that refugees and migrants are integral to health systems, not just as recipients of care but also as health workers and community leaders. The inclusion of these populations in health systems is crucial for societal benefits and enhances preparedness for future health challenges. Despite the progress, the report identifies significant gaps in data collection and health service inclusion for refugees and migrants. Only 37% of countries routinely collect migration-related health data, and less than 40% train health workers in culturally responsive care. The report calls for urgent action from governments and partners to embed refugees and migrants in national health strategies, improve data collection, and engage these communities in health governance. WHO plans to continue supporting member states in translating commitments into action, focusing on culturally responsive care and integrating refugees and migrants into resilient health systems. The organization is also collaborating with partners like the International Organization for Migration (IOM) to enhance digital health systems that facilitate access to health records for migrants, ensuring continuity of care across borders.

WHO Outbreak News · Mar 26

Child Mortality Rates Stagnate as 4.9 Million Children Die Before Age Five in 2024

In 2024, an estimated 4.9 million children died before reaching their fifth birthday, with 2.3 million of these deaths occurring in newborns, according to the latest report from UNICEF. While global under-five mortality rates have decreased by over 50% since 2000, the pace of reduction has significantly slowed since 2015, dropping by more than 60%. This stagnation is alarming, especially given that many of these deaths are preventable through low-cost interventions and improved access to quality healthcare. The report highlights severe acute malnutrition (SAM) as a direct cause of death for over 100,000 children aged 1-59 months, representing 5% of under-five deaths. The impact of malnutrition is compounded by its indirect effects, which weaken immunity and increase vulnerability to common childhood diseases. Countries such as Pakistan, Somalia, and Sudan are among those with the highest mortality rates, particularly concerning newborn deaths, which account for nearly half of all under-five fatalities. The leading causes of newborn deaths include complications from preterm birth and issues during labor and delivery. Infectious diseases remain a significant threat, with malaria being the leading cause of death in this age group, particularly in sub-Saharan Africa, where 58% of all under-five deaths occur. The report underscores the urgent need for investment in quality antenatal care and skilled healthcare personnel to address these preventable conditions. Furthermore, children in fragile and conflict-affected regions are nearly three times more likely to die before age five compared to those in more stable environments. The report also notes that 2.1 million individuals aged 5-24 died in 2024, with infectious diseases and injuries being the primary causes. As global development financing shifts, maternal, newborn, and child health programs face increasing pressure, necessitating sustained funding to protect and accelerate progress. Investments in child health are among the most cost-effective measures, with every dollar spent potentially yielding up to twenty dollars in social and economic benefits. To reverse the trend of stagnating child mortality rates, it is crucial for governments and partners to prioritize child survival, enhance access to quality services, and strengthen healthcare systems.

WHO Outbreak News · Mar 18

WHO Updates Influenza Vaccine Recommendations for 2026-2027 Northern Hemisphere Season

The World Health Organization (WHO) has released its recommendations for the composition of influenza vaccines for the upcoming 2026-2027 northern hemisphere season. This decision follows a comprehensive four-day consultation that analyzed global influenza surveillance data, emphasizing the need for regular updates to vaccine formulations due to the constantly evolving nature of influenza viruses. The recommendations are critical as they guide national regulatory agencies and pharmaceutical companies in developing vaccines that are closely aligned with the circulating strains, thereby enhancing protection against severe illness and mortality. The recent emergence of a new variant of the A(H3N2) virus, classified as J.2.4.1 or 'subclade K', has been a significant factor in the decision-making process. This variant has led to an earlier onset of the influenza season in many regions, with reports indicating higher-than-normal activity levels. The WHO noted that influenza A viruses remain predominant, with subclade K accounting for the majority of reported cases, while influenza B viruses have been less prevalent. In addition to seasonal strains, the WHO also assessed zoonotic influenza viruses, which pose a potential pandemic threat. Since September 2025, 25 human infections with zoonotic influenza have been reported across six countries, primarily linked to exposure to infected animals. Fortunately, no human-to-human transmission has been documented. The WHO's ongoing surveillance and biannual consultations are crucial for identifying new candidate vaccine viruses (CVVs) that can be rapidly deployed in response to emerging threats. For the 2026-2027 season, WHO recommends specific strains for both egg-based and cell culture-based vaccines, including A/Missouri/11/2025 (H1N1)pdm09-like and A/Darwin/1454/2025 (H3N2)-like viruses. The recommendations underscore the importance of global collaboration in addressing the shared risks posed by influenza and ensuring that communities are adequately protected against this widespread respiratory infection.

WHO Outbreak News · Feb 27

Libya Achieves WHO Validation for Trachoma Elimination as Public Health Concern

The World Health Organization (WHO) has officially recognized Libya's successful elimination of trachoma as a public health problem, marking a significant milestone for the country and the Eastern Mediterranean Region. This achievement not only protects future generations from preventable blindness but also serves as a testament to Libya's resilience in combating neglected tropical diseases amidst ongoing challenges. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized that this accomplishment reflects Libya's commitment to safeguarding public health and demonstrates that progress against neglected tropical diseases is achievable in all regions. Libya is now the 28th country globally and the 8th in the Eastern Mediterranean to eliminate trachoma, showcasing the effectiveness of evidence-based programming and coordinated support in overcoming health challenges. The journey towards this achievement began with the Ministry of Health prioritizing trachoma elimination in 2017, supported by organizations such as WHO, Sightsavers, and the International Trachoma Initiative. Surveys conducted in 2022 confirmed that the prevalence of active trachoma and trichiasis fell below WHO's elimination thresholds, with a follow-up survey in 2025 further validating this progress. The success of Libya's trachoma elimination program is particularly remarkable given the backdrop of political instability and humanitarian crises that have strained health services and displaced populations. Despite these adversities, the program effectively integrated surveillance, expanded surgical care access, and built capacity among healthcare workers. Dr. Mohamed Al-Ghoj, Acting Minister of Health, highlighted the dedication of health workers in reaching every district to ensure comprehensive eye health services. This validation not only brings pride to Libya but also contributes to the global fight against neglected tropical diseases, which affect over one billion people worldwide. With the elimination of trachoma, Libya joins a growing list of countries that have successfully tackled these diseases, reinforcing the importance of international collaboration and commitment to public health goals. The WHO continues to support endemic countries in their efforts to eliminate trachoma and other neglected tropical diseases as part of the global health agenda.

WHO Outbreak News · Feb 18

WHO Member States Progress on Pathogen Access and Benefit Sharing Annex for Pandemic Agreement

Member States of the World Health Organization (WHO) have concluded a weeklong negotiation session focused on the draft annex for Pathogen Access and Benefit Sharing (PABS), a crucial element of the WHO Pandemic Agreement. This fifth meeting of the Intergovernmental Working Group (IGWG) took place from February 9 to 14, 2026, and aimed to enhance global preparedness for future pandemics by ensuring rapid detection and sharing of pathogens with pandemic potential. The PABS system is designed to facilitate equitable access to pathogen materials and genetic data, which is essential for the swift development of diagnostics, treatments, and vaccines. Ambassador Tovar da Silva Nunes of Brazil, co-chair of the IGWG, emphasized the commitment of countries to finalize the PABS annex, highlighting the need for streamlined text while addressing contentious issues through further consultation. The next round of negotiations is scheduled for next month, with a deadline set for May, when the outcomes will be presented to the World Health Assembly (WHA). Mr. Matthew Harpur from the United Kingdom, also a co-chair, acknowledged the progress made but noted that significant differences remain, stressing the urgency of bridging these gaps. The WHO Pandemic Agreement, adopted last year, aims to rectify the global weaknesses exposed by the COVID-19 pandemic and enhance international collaboration. WHO Director-General Dr. Tedros Adhanom Ghebreyesus reiterated the importance of multilateralism in addressing future pandemics and expressed confidence in reaching an agreement on the PABS annex by the upcoming WHA. The negotiations also included engagement with stakeholders from the private sector, academia, and laboratories, underscoring the collaborative effort required to strengthen global health security.

WHO Outbreak News · Feb 17

WHO Raises Ethical Concerns Over Hepatitis B Vaccine Trial in Guinea-Bissau

The World Health Organization (WHO) has issued a statement regarding a proposed randomized controlled trial (RCT) of the hepatitis B birth dose vaccine in Guinea-Bissau, expressing significant ethical concerns. The hepatitis B birth dose vaccine is a critical public health intervention that has been proven effective in preventing mother-to-child transmission of the virus, which can lead to severe liver disease. With over 115 countries incorporating this vaccine into their national immunization schedules, its timely administration is essential for both individual and public health outcomes. WHO's concerns center on the ethical implications of withholding the vaccine from some participants in the trial, as this could expose newborns to serious health risks, including chronic infection and liver cancer. The organization emphasizes that the vaccine has a well-established safety record and is effective in preventing 70-95% of mother-to-child transmissions. The trial's design, which includes a no-treatment arm, lacks scientific justification, as there is no critical question of efficacy or safety that necessitates such an approach. The WHO also highlights that the trial's single-blind, no-treatment-controlled design raises the potential for bias, which could undermine the validity of the results. Ethical research principles dictate that proven interventions should not be withheld from participants, especially when resource constraints cannot justify such actions. As a result, Guinea-Bissau has suspended the study pending further review. Moving forward, WHO is committed to supporting Guinea-Bissau in the introduction of the hepatitis B birth dose vaccine, which is planned for 2028. This includes strategies for timely delivery, antenatal screening, and training for healthcare workers. The organization aims to ensure that all newborns receive timely protection against hepatitis B, adhering to the highest ethical and scientific standards in research.

WHO Outbreak News · Feb 13

UN Leaders Urge Action as 4.5 Million Girls Face Female Genital Mutilation Risk in 2026

On the International Day of Zero Tolerance for Female Genital Mutilation (FGM), UN leaders have issued a joint statement highlighting the urgent need to address the ongoing risk faced by an estimated 4.5 million girls, many under the age of five, who are projected to undergo FGM in 2026. Currently, over 230 million women and girls live with the severe and lifelong consequences of this harmful practice, which is recognized as a violation of human rights. The health implications are dire, with treatment costs for complications estimated at around $1.4 billion annually. The statement emphasizes that while progress has been made in recent years—evidenced by a reduction in the prevalence of FGM from one in two girls to one in three—sustained commitment and investment are crucial to continue this momentum. The UN leaders stress that nearly two-thirds of populations in FGM-prone countries support its elimination, indicating a growing awareness and willingness to change cultural practices. To meet the Sustainable Development Goal of ending FGM by 2030, the UN calls for increased investment in community-led initiatives, health education, and engagement with local leaders. They highlight that every dollar spent on ending FGM can yield a tenfold return, with an investment of $2.8 billion potentially preventing 20 million cases and generating $28 billion in returns. However, current funding cuts and declining international support threaten these efforts, risking a reversal of progress made over the past decades. The UN leaders reaffirm their commitment to collaborate with public and private partners, including survivors, to ensure comprehensive support for those affected by FGM. They urge for a renewed focus on prevention strategies and adequate financing to protect millions of girls from this harmful practice as the 2030 deadline approaches.

WHO Outbreak News · Feb 5

Assessing Global Pandemic Preparedness Six Years Post-COVID-19 Declaration

As the world marks six years since the World Health Organization (WHO) declared COVID-19 a Public Health Emergency of International Concern (PHEIC), the question arises: Is the global community better prepared for future pandemics? The WHO acknowledges progress in pandemic preparedness, citing significant advancements made since the onset of COVID-19. However, the organization also warns that these improvements are fragile and uneven, necessitating ongoing efforts to enhance global health security. Key developments include the adoption of the historic WHO Pandemic Agreement in May 2025, which aims to establish a comprehensive framework for pandemic prevention and response. Member States are currently negotiating the Pathogen Access and Benefits Sharing (PABS) system, which is expected to facilitate the agreement's implementation as international law. Additionally, the Pandemic Fund, co-founded by WHO and the World Bank, has allocated over $1.2 billion in grants, catalyzing an additional $11 billion for 67 projects across 98 countries to bolster surveillance and response capabilities. The WHO has also launched initiatives to improve genomic surveillance and pandemic intelligence, including the update of the Epidemic Intelligence from Open Sources (EIOS) system, which utilizes AI to assist over 110 countries in threat identification. Furthermore, the Global Health Emergency Corps was established in 2023 to address gaps identified during the COVID-19 response, providing rapid support to countries facing public health emergencies. Despite these advancements, challenges remain. The WHO emphasizes the need for continued collaboration and investment in health systems to ensure equitable access to vaccines, diagnostics, and treatments, particularly in low- and middle-income countries. As the global community reflects on the lessons learned from COVID-19, the focus must remain on strengthening preparedness to mitigate the impact of future pandemics.

WHO Outbreak News · Feb 2